The inclusion criteria were the following (1): NMDARe (2); clinical and/or MRI findings compatible with MS or AQP4-Ab-positive NMOSD, or MOGAD; and (3) seropositivity for MOG-IgG or AQP4-IgG and cerebrospinal fluid positivity for NMDA receptor antibodies, with positivity confirmed by cell-based assays. Here, AQP4 is linked to myeloid sarcoma.